Future directions in the treatment of patients with chronic hepatitis C virus infection

Canadian Journal of Gastroenterology

Volumn 13, Issue 1, 1999, Pages 57-62

  Gish, Robert G ^a,b  

^a CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^b NONE   (United States)

Author keywords

Antiviral therapy; Hepatitis C; Hepatitis C virus helicase; Hepatitis C virus proteinases; Hepatitis C virus RNA polymerase; Interferon

Indexed keywords

ALPHAN1 INTERFERON; ANTISENSE OLIGONUCLEOTIDE; CONSENSUS INTERFERON; DNA VACCINE; HEPATITIS VACCINE; INTERFERON; REBETRON; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; RIBOZYME; THYMOSIN ALPHA1; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANTIVIRAL ACTIVITY; BIOTECHNOLOGY; CELL CULTURE; CHRONIC HEPATITIS; DRUG EFFICACY; DRUG SCREENING; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CANCER; LIVER CIRRHOSIS; LIVER FAILURE; LIVER TRANSPLANTATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; VIRUS GENOME; VIRUS MUTANT; VIRUS REPLICATION; VIRUS TRANSCRIPTION;

EID: 0032950866     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: 10.1155/1999/309272     Document Type: Review

References (78)

1. National Institutes of Health Consensus Development Conference Panel statement: management of hepatitis C. Hepatology 1997;26:2S-10S.
2. Alter MJ. Epidemiology of hepatitis C. Hepatology 1997;26:62S-5S.
3. Carithers RLJ, Emerson SS. Therapy of hepatitis C: meta-analysis of interferon alfa-2b trials. Hepatology 1997;26:83S-8S.
4. Lam NP, Neumann AU, Gretch DR, Wiley TE, Perelson AS, Layden TJ. Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa. Hepatology 1997;26:226-31.
5. Cianciara J, Laskus T. Thymic factor X treatment of chronic hepatitis B. Hepatology 1992;16:1507-8.
6. Dworniak D, Tchorzewski H, Pokoca L, et al. Treatment with thymic extract TFX for chronic active hepatitis B. Arch Immunol Ther Exp (Warsz) 1991;39:537-47.
7. Fattovich G, Giustina G, Alberti A, et al. A randomized controlled trial of thymopentin therapy in patients with chronic hepatitis B. J Hepatol 1994;21:361-6.
8. Galli M, Crocchiolo P, Negri C, Caredda F, Lazzarin A, Moroni M. Attempt to treat acute type B hepatitis with an orally administered thymic extract (thymomodulin): preliminary results. Drugs Exp Clin Res 1985;11:665-9.
9. Mutchnick MG, Ehrinpreis MN, Kinzie JL, Peleman RR. Prospectives on the treatment of chronic hepatitis B and chronic hepatitis C with thymic peptides and antiviral agents. Antiviral Res 1994;24:245-57.
10. Romeo F, Arcoria D, Palmisano L, Polosa P. Effectiveness of thymostimulin treatment in hepatitis B surface antigen-positive chronic active liver disease. Results of a randomized clinical trial. Arzneimittelforschung 1985;35:1317-22.
11. Romeo F, Palmisano L, Arcoria D. Thymostimulin in the treatment of hepatitis B surface antigen-positive chronic active hepatitis. Controlled clinical trial - two years follow-up. Arzneimittelforschung 1987;37:450-6.
12. Zaruba K, Rastorfer M, Grob PJ, Joller-Jemelka H, Bolla K. Thymopentin as adjuvant in non-responders or hyporesponders to hepatitis B vaccination. Lancet 1983;ii:1245-5.
13. Eichberg JW, Seeff LB, Lawlor DL, et al. Effect of thymosin immunostimulation with and without corticosteroid immunosuppression on chimpanzee hepatitis B carriers. J Med Virol 1987;21:25-37.
14. Andreone P, Cursaro C, Gramenzi A, et al. A randomized controlled trial of thymosin-alpha1 versus interferon alfa treatment in patients with hepatitis B e antigen antibody - and hepatitis B virus DNA - positive chronic hepatitis B. Hepatology 1996;24:774-7.
15. Davis GL. Treatment of chronic hepatitis B. Hepatology 1991;14:567-9.
16. Mutchnick MG, Appelman HD, Chung HT, et al. Thymosin treatment of chronic hepatitis B: a placebo-controlled pilot trial. Hepatology 1991;14:409-15.
17. Rasi G, DiVirgilio D, Mutchnick MG, et al. Combination thymosin alpha 1 and lymphoblastoid interferon treatment in chronic hepatitis C. Gut 1996;39:679-83.
18. Mutchnick MG, Lindsay KL, Schiff ER, Cummings GD, Appelman HD. Thymosin α-1 treatment of chronic hepatitis B: a multicenter randomized, placebo-controlled double blind study. Gastroenterology 1995;108:a1127. (Abst)
19. Ning Q, Brown D, Parodo J, et al. Ribavirin inhibits viral-induced macrophage production of TNF, IL-1, the procoagulant fgl2 prothrombinase and preserves Th1 cytokine production but inhibits Th2 cytokine response. J Immunol 1998;160:3487-93.
20. White DO. Antiviral chemotherapy. Med J Aust 1984;140:715-20.
21. Acero D, Adrados M, González-Huix F, Figa M. Ribavirin treatment in patients with chronic hepatitis C refractory to interferon-alpha. Gastroenterol Hepatol 1996;19:243-6.
22. Bodenheimer HCJ, Lindsay KL, Davis GL, Lewis JH, Thung SN, Seeff LB. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial. Hepatology 1997;26:473-7.
23. Camps J, Garcia N, Riezu-Boj JI, Civeira MP, Prieto J. Ribavirin in the treatment of chronic hepatitis C unresponsive to alfa interferon. J Hepatol 1993;19:408-12.
24. Di Bisceglie AM, Conjeevaram HS, Fried MW, et al. Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995;123:897-903.
25. Di Bisceglie AM, Shindo M, Fong TL, et al. A pilot study of ribavirin therapy for chronic hepatitis C. Hepatology 1992;16:649-54.
26. Dusheiko G, Main J, Thomas H, et al. Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study. J Hepatol 1996;25:591-8.
27. Fried MW, Hoofnagle JH. Therapy of hepatitis C. Semin Liver Dis 1995;15:82-91.
28. Koskinas J, Tibbs C, Saleh MG, Pereira LM, McFarlane IG, Williams R. Effects of ribavirin on intrahepatic and extrahepatic expression of hepatitis C virus in interferon nonresponsive patients. J Med Virol 1995;45:29-34.
29. Reichard O, Andersson J, Schvarcz R, Weiland O. Ribavirin treatment for chronic hepatitis C. Lancet 1991;337:1058-61.
30. Reichard O, Yun ZB, Sonnerborg A, Weiland O. Hepatitis C viral RNA titers in serum prior to, during, and after oral treatment with ribavirin for chronic hepatitis C. J Med Virol 1993;41:99-102.
31. Schvarcz R, Yun ZB, Sonnerborg A, Weiland O. Combined treatment with interferon alpha-2b and ribavirin for chronic hepatitis C in patients with a previous non-response or non-sustained response to interferon alone. J Med Virol 1995;46:43-7.
32. Brillanti S, Garson J, Foli M, et al. A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C. Gastroenterology 1994;107:812-7.
33. Lai MY, Kao JH, Yang PM, et al. Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C. Gastroenterology 1996;111:1307-12.
34. Reichard O, Norkrans G, Fryden A, Braconier JH, Sonnerborg A, Weiland O. Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group. Lancet 1998;351:83-7.
35. Reichard O, Schvarcz R, Weiland O. Therapy of hepatitis C: alpha interferon and ribavirin. Hepatology 1997;26:108S-11S.
36. Schalm SW, Brouwer JT, Chemello L, et al. Interferon-ribavirin combination therapy for chronic hepatitis C. Dig Dis Sci 1996;41:131S-4S.
37. Schalm SW, Hansen BE, Chemello L, et al. Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patient data from European centers. J Hepatol 1997;26:961-6.
38. Davis GL, Esteban-Mur R, Rustgi V, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med 1998;339:1493-9.
39. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998;339:1485-92.
40. Bizollon T, Palazzo U, Ducerf C, et al. Pilot study of the combination of interferon alfa and ribavirin as therapy of recurrent hepatitis C after liver transplantation. Hepatology 1997;26:500-4.
41. Major ME, Feinstone SM. The molecular virology of hepatitis C. Hepatology 1997;25:1527-38.
42. Behrens SE, Tomei L, De Francesco R. Identification and properties of the RNA-dependent RNA polymerase of hepatitis C virus. EMBO J 1998;15:12-22.
43. Gwack Y, Kim DW, Han JH, Choe J. Characterization of RNA binding activity and RNA helicase activity of the hepatitis C virus NS3 protein. Biochem Biophys Res Commun 1996;225:654-9.
44. Gwack Y, Kim DW, Han JH, Choe J. DNA helicase activity of the hepatitis C virus nonstructural protein 3. Eur J Biochem 1997;250:47-54.
45. Hong Z, Ferrari E, Wright-Minogue J, et al. Enzymatic characterization of hepatitis C virus NS3/4A complexes expressed in mammalian cells by using the herpes simplex virus amplicon system. J Virol 1996;70:4261-8.
46. Kim DW, Gwack Y, Han JH, Choe J. C-terminal domain of the hepatitis C virus NS3 protein contains an RNA helicase activity. Biochem Biophys Res Commun 1995;215:160-6.
47. Kim DW, Gwack Y, Han JH, Choe J. Towards defining a minimal functional domain for NTPase and RNA helicase activities of the hepatitis C virus NS3 protein. Virus Res 1997;49:17-25.
48. Kim DW, Kim J, Gwack Y, Han JH, Choe J. Mutational analysis of the hepatitis C virus RNA helicase. J Virol 1997;71:9400-9.
49. Yao N, Hesson T, Cable M, et al. Structure of the hepatitis C virus RNA helicase domain. Nat Struct Biol 1997;4:463-7.
50. Hirowatari Y, Hijikata M, Shimotohno K. A novel method for analysis of viral proteinase activity encoded by hepatitis C virus in cultured cells. Anal Biochem 1995;225:113-20.
51. Hirowatari Y, Hijikata M, Tanji Y, Shimotohno K. Expression and processing of putative nonstructural proteins of hepatitis C virus in insect cells using baculovirus vector. Virus Res 1995;35:43-61.
52. Kakiuchi N, Hijikata M, Komoda Y, Tanji Y, Hirowatari Y, Shimotohno K. Bacterial expression and analysis of cleavage activity of HCV serine proteinase using recombinant and synthetic substrate. Biochem Biophys Res Commun 1995;210:1059-65.
53. Kakiuchi N, Komoda Y, Hijikata M, Shimotohno K. Cleavage activity of hepatitis C virus serine proteinase. J Biochem (Tokyo ) 1997;122:749-55.
54. Shimotohno K, Tanji Y, Hirowatari Y, Komoda Y, Kato N, Hijikata M. Processing of the hepatitis C virus precursor protein. J Hepatol 1995;22:87-92.
55. Feller JA, Carroll AR, Sangar DV, Lau JYN, Clarke BE. Expression of enzymatically active HCV NS3 protease (genotype 1b) and the development of an in-vitro protease assay system. Hepatology 1995;22:A897. (Abst)
56. Chayama K, Tsubota A, Kobayashi M, et al. Pretreatment virus load and multiple amino acid substitutions in the interferon sensitivity-determining region predict the outcome of interferon treatment in patients with chronic genotype 1b hepatitis C virus infection. Hepatology 1997;25:745-9.
57. Enomoto N, Sakuma I, Asahina Y, et al. Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region. J Clin Invest 1995;96:224-30.
58. Enomoto N, Sakuma I, Asahina Y, et al. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 1996;334:77-81.
59. Kurosaki M, Enomoto N, Murakami T, et al. Analysis of genotypes and amino acid residues 2209 to 2248 of the NS5A region of hepatitis C virus in relation to the response to interferon-beta therapy. Hepatology 1997;25:750-3.
60. Sato C, Enomoto N. Specific hepatitis C virus NS5A sequences determine the outcome of interferon treatment. Gastroenterology 1996;111:1152-4.
61. Alt M, Renz R, Hofschneider PH, Paumgartner G, Caselmann WH. Specific inhibition of hepatitis C viral gene expression by antisense phosphorothioate oligodeoxynucleotides. Hepatology 1995;22:707-7.
62. Wakita T, Wands JR. Specific inhibition of hepatitis C virus expression by antisense oligodeoxynucleotides. In vitro model for selection of target sequence. J Biol Chem 1994;269:14205-10.
63. Branch AD, Robertson HD. Efficient trans cleavage and a common structural motif for the ribozymes of the human hepatitis delta agent. Proc Natl Acad Sci USA 1991;88:10163-7.
64. Offensperger WB, Blum HE, Gerok W. Molecular therapeutic strategies in hepatitis B virus infection. Clin Invest 1994;72:737-41.
65. Prasad Y, Smith JB, Gottlieb PA, Bentz J, Dinter-Gottlieb G. Deriving a 67-nucleotide trans-cleaving ribozyme from the hepatitis delta virus antigenomic RNA. Antisense Res Dev 1992;2:267-77.
66. Sakamoto N, Wu CH, Wu GY. Inhibition of hepatitis C virus-directed translation by hammerhead ribozymes in-vitro. Hepatology 1995;22:A896. (Abst)
67. Farci P, Alter HJ, Govindarajan S, et al. Lack of protective immunity against reinfection with hepatitis C virus. Science 1992;258:135-40.
68. Michel ML, Davis HL, Schleef M, Mancini M, Tiollais P, Whalen RG. DNA-mediated immunization to the hepatitis B surface antigen in mice: aspects of the humoral response mimic hepatitis B viral infection in humans. Proc Natl Acad Sci USA 1995;92:5307-11.
69. Tokushige K, Wakita T, Pachuk C, et al. Expression and immune response to hepatitis C virus core DNA- based vaccine constructs. Hepatology 1996;24:14-20.
70. Holzmayer TA, Pestov DG, Roninson IB. Isolation of dominant negative mutants and inhibitory antisense RNA sequences by expression selection of random DNA fragments. Nucleic Acids Res 1992;20:711-7.
71. Endres CL, Bergquam EP, Axthelm MK, Wong SW. Suppression of simian immunodeficiency virus replication by human immunodeficiency virus type 1 trans-dominant negative rev mutants. J Virol 1995;69:5164-6.
72. Weber PC, Wigdahl B. Identification of dominant-negative mutants of the herpes simplex virus type 1 immediate-early protein ICP0. J Virol 1992;66:2261-7.
73. Daugherty D. Genetic structure and heterogeneity of hepatitis C virus: a vaccine impediment? Hepatology 1992;15:739-41.
74. Farci P, Alter HJ, Wong DC, et al. Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization. Proc Natl Acad Sci USA 1994;91:7792-6.
75. Farci P, Shimoda A, Wong D, et al. Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein. Proc Natl Acad Sci USA 1996;93:15394-9.
76. Piazza M, Sagliocca L, Tosone G, et al. Sexual transmission of the hepatitis C virus and efficacy of prophylaxis with intramuscular immune serum globulin. A randomized controlled trial. Arch Intern Med 1997;157:1537-44.
77. Purcell R. The hepatitis C virus: overview. Hepatology 1997;26:11S-4S.
78. Shimizu YK, Igarashi H, Kiyohara T, et al. A hyperimmune serum against a synthetic peptide corresponding to the hypervariable region 1 of hepatitis C virus can prevent viral infection in cell cultures. Virology 1996;223:409-12.